Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the
biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast
proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.